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Abstract
Display technology refers to methods of generating libraries of modularly coded biomolecules and screening them for particular
properties. Retroviruses are good candidates to be a eukaryotic viral platform for the display of polypeptides synthesized in eukaryotic cells.
Here we demonstrate that avian leukosis virus (ALV) provides an ideal platform for display of nonviral polyaeptides expressed in a
eukaryotic cell substrate. Different sizes of polypeptides were genetically fused to the extreme N-terminus of the ALV envelope
glycoprotein in an ALV infectious clone containing an alkaline phosphatase reporter gene. The chimeric envelope glycoproteins were
efficiently incorporated into virions and were stably displayed on the surface of the virions through multiple virus replication cycles. The
foreign polypeptides did not interfere with the attachment and entry functions of the underlying ALV envelope glycoproteins. The displayed
polypeptides were fully functional and could efficiently mediate attachment of the recombinant viruses to their respective cognate receptors.
This study demonstrates that ALV is an ideal display platform for the generation and selection of libraries of polypeptides where there is
a need for expression, folding, and posttranslational modification in the endoplasmic reticulum of eukaryotic cells.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
Display technology refers to methods of generating li-
braries of modularly coded biomolecules and screening
them for particular properties (see reviews Bradbury, 1999,
2000; Li, 2000). The key feature of display technology is
the linkage of a particular phenotype (displayed polypep-
tide) to its genotype (gene encoding the displayed polypep-
tide), enabling the rapid identification of the selected
polypeptide(s). Retroviruses are good candidates to be a
eukaryotic viral platform for the display of polypeptides
synthesized in eukaryotic cells. Retroviruses are enveloped
viruses expressed and amplified in eukaryotic host cells and
are heavily glycosylated, negatively charged, and soluble in
body fluids. Retroviral envelope glycoproteins are oli-
gomers of two glycoproteins, the surface glycoprotein (SU),
which contains the major domains that interact with the host
receptor, and the transmembrane glycoprotein (TM), which
anchors SU to the membrane and mediates fusion of the
viral and cellular membranes required for entry (reviewed in
Hunter, 1997). Eukaryotic cells also have an efficient qual-
ity control system that assesses whether a protein has been
properly folded and modified, including retroviral glyco-
proteins, before transport to the cell surface and incorpora-
tion into virions [reviewed in Braakman and van Anken,
2000; Chevet et al., 2001].
The potential of retroviruses as vehicles for the display
of polypeptides, the generation of polypeptide display li-
braries, and their selection against eukaryotic cellular tar-
gets has been demonstrated using a murine retrovirus, mu-
rine leukemia virus (MLV) (reviewed in Russell and Cosset,
1999). Although nonviral peptides, growth factors, and sin-
gle-chain antibodies have been successfully displayed on
the SU glycoprotein of MLV, there are several serious
drawbacks that limit the usefulness of MLV as an efficient
platform for polypeptide display. The principle limitation is
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the weak, noncovalent interaction between the MLV SU and
TM glycoproteins which results in significant shedding of
SU (99%) and the linked nonviral polypeptide from the
viral particles (Cosset et al., 1995). In addition, the display
of some polypeptides on MLV SU has blocked subsequent
viral infection of normally susceptible cells, restricting the
versatility of MLV as an inert display platform (Cosset et
al., 1995; Nilson et al., 1996). Finally, the infectivity of
MLV displaying nonviral polypeptide fusions with SU is
significantly decreased compared to wild-type MLV (50- to
100-fold lower), which limits the maximum diversity attain-
able with a polypeptide library displayed on MLV (Ager et
al., 1996).
A different retrovirus, the avian leukosis virus (ALV),
offers several advantages over MLV as a eukaryotic viral
platform for the display of polypeptides. First, the ALV SU
and TM envelope glycoproteins are covalently bound
through a stable disulfide bond; little or no SU is normally
shed from ALV particles (Bolognesi et al., 1972; Einfeld
and Hunter, 1988; Leamnson and Halpern, 1976). Second, a
series of replication-competent ALV-based retroviral vec-
tors has been developed and characterized, and these vectors
are capable of stably maintaining an additional nonviral
gene (see review Federspiel and Hughes, 1997). The ability
of the ALV genome to maintain at least 2.5 kb of additional
sequence extends the possible sizes of the displayed
polypeptides and/or offers space for an independent gene to
encode a reporter protein or a second library of displayed
polypeptides. Third, these vectors replicate to high titers in
avian cells, but do not infect mammalian cells that lack the
appropriate receptors. Therefore, ALV could also be used as
a stable, soluble, relatively inert platform for the display and
selection of peptide libraries in mouse xenograft tumor
models since mammalian cells do not express receptors for
ALV. The goal of this study was to determine if nonviral
polypeptides can be efficiently displayed on ALV envelope
glycoproteins and then to to define the characteristics of
polypeptide display on replication-competent ALV.
Results and discussion
Construction of chimeric ALV env genes encoding
nonviral polypeptides
Since there are no crystallographic data on the three-
dimensional structure of the ALV envelope glycoproteins,
we constructed chimeric ALV envelope glycoproteins mod-
eled on a successful MLV polypeptide display strategy:
extension of the N-terminus of the mature SU glycoprotein
using amino acid spacers (Valesesia-Wittmann et al., 1996).
Key parameters of efficient N-terminal display on MLV SU
were the spacing between the displayed polypeptides and
the SU N-terminus, and the addition of linker domains
having conformational flexibility to allow both the proper
folding and the oligomerization of the glycoproteins and to
increase the accessibility of the displayed domains to recep-
tors. Chimeric ALV(A) env genes encoding several differ-
ent combinations of polypeptide ligands and flexible amino
acid linkers were constructed to determine if ALV would
tolerate additional nonviral domains fused to the envelope
glycoproteins in a replication-competent virus, and to test
the effect of several different sizes of polypeptides and
linker lengths on ALV display (Fig. 1). Three different
epitopes were displayed: a small 8-amino-acid antibody
epitope (FLAG tag), a 51-amino-acid growth factor [epi-
dermal growth factor (EGF)], and a 244-amino-acid single-
chain antibody (-CEAscFv). Single or multiple copies of a
flexible linker [glycine-glycine-glycine-glycine-serine
(G4S)] were used to tether the displayed polypeptide to the
ALV SU N-terminus and a recognition site for Factor Xa
protease (IEGR) was included to provide a means to cleave
the nonviral domains from the ALV glycoproteins. The
restriction endonuclease sites used for cloning, SfiI and
NotI, encoded additional amino acids flanking the displayed
Fig. 1. Schematic representation of the replication-competent ALV-based
retroviral vector, RCASBP(A)AP, and the wild-type and chimeric enve-
lope glycoproteins used in this study. The RCASBP(A)AP vector contains
the gag, pol, and subgroup A env viral genes, and a heat-stable alkaline
phosphatase (AP) reporter gene, flanked by long terminal repeats (LTR).
The envelope glycoproteins are translated from a spliced mRNA and
contain a signal peptide followed by a protease cleavage site at the start of
the mature surface glycoprotein (1). Nonviral epitopes were inserted
in-frame at the N-terminus of SU (1) in all chimeric envelope glyco-
proteins constructed: the eight-amino-acid FLAG epitope tag (DYKD-
DDDK); the amino acids encoded by the SfiI restriction enzyme site
(AAQPA); the 51-amino-acid human epidermal growth factor (EGF) li-
gand; the 244-amino-acid anti-carcinoembryonic antigen single-chain an-
tibody; different combinations of an amino acid linker, glycine-glycine-
glycine-glycine-serine (G4S), to provide flexibility to the ligands; the
Factor Xa (Fxa) protease cleavage site (IEGR); and the amino acids
encoded by the NotI restriction enzyme site (AAA). SD, splice donor; SA,
splice acceptor.
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polypeptides. All of the chimeric env genes were cloned into
the RCASBP(A)AP replication-competent vector contain-
ing an alkaline phosphatase (AP) reporter gene.
The chimeric envelope glycoproteins are efficiently
expressed and incorporated into infectious ALV virions
Virus stocks of ALV with a wild-type env gene (A), or
chimeric env genes encoding an N-terminal FLAG tag,
different protease cleavable linkers, and plus or minus
the EGF domain [F(A), FEXL(A), FELXL(A), and
FEXL3(A)], were produced by transfecting plasmid DNA
encoding the infectious molecular clones into chicken DF-1
cells, and the viruses were allowed to spread through the
culture (Fig. 2A). All viruses replicated efficiently, although
the viruses with chimeric envelope glycoproteins produced
slightly lower titer stocks (three- to five-fold) compared to
wild-type (Table 1). Virions from each virus stock were
collected and the envelope glycoproteins were analyzed by
Western immunoblot (Figs. 2B and C). Only the virions
with the chimeric glycoproteins contained the expected non-
viral polypeptides as detected with monoclonal antibodies
that recognize the FLAG or EGF domains (Fig. 2B). The
ALV(A) SU glycoprotein was detected in immunoblots of
all viruses with an obvious decrease in glycoprotein mobil-
ity observed with the EGF-containing proteins (Fig. 2C).
The conformation of the displayed nonviral polypeptides on
the envelope glycoproteins in virions was susceptible to
Factor Xa protease cleavage. The mobility of the chimeric
glycoproteins was similar to wild-type after protease cleav-
age (Fig. 2C) due to the loss of the FLAG and/or EGF
epitopes (data not shown). In contrast to polypeptide display
on phage, the vast majority of the ALV(A) SU glycoprotein
population retained the nonviral polypeptide fusion
(Fig. 2C).
The nonviral ligands displayed on ALV specifically bind
their cognate receptor
To determine if the nonviral polypeptides fused to the
glycoproteins in ALV virions were properly folded and
could specifically bind an appropriate receptor, virions were
incubated with receptors immobilized on a solid support or
expressed on a cell surface (Fig. 3). Monoclonal antibodies
that recognize either FLAG or human EGF were bound to
plates and incubated with ALV(A) containing wild-type or
chimeric envelope glycoproteins. After washing the un-
bound viruses away, the bound viruses were detected by
adding DF-1 cells to the culture to propagate the bound
viruses and the infected cells were scored for AP activity
(Fig. 3A). Only viruses with chimeric envelope glycopro-
Fig. 2. Replication of RCASBP(A)AP viruses with wild-type and chimeric envelope glycoproteins. (A) Plasmids encoding infectious molecular clones of
RCASBP(A)AP with a wild-type env (A) or chimeric env F(A), FEXL(A), FELXL(A), or FEXL3(A) were transfected into chicken DF-1 cells and the cultures
were propagated. Viral growth was monitored by ELISA for ALV capsid protein in the culture supernatants [optical density (OD) at 490 nm]. (B and C)
Western immunoblot analysis of viral proteins in virions collected from day 22 posttransfection supernatants (3 ml). Proteins were also analyzed from
uninfected DF-1 cell supernatant (Mock). The antibody-bound protein complexes were visualized by chemiluminescence. The molecular sizes are in
kilodaltons. (B) The SU glycoproteins were analyzed for the presence of ALV capsid protein (-CA) for the FLAG tag with an anti-FLAG mAb (-FLAG)
and for the EGF ligand with an anti-EGF mAb (-EGF). (C) The accessibility of the Factor Xa site in the chimeric glycoproteins to protease cleavage was
determined. Viral proteins were incubated with () or without () Factor Xa protease (Fxa) and the results were analyzed by immunoblot using an anti-ALV
SU mAb [-ALV(A)SU].
Table 1
Titers of RCASBP(A)AP viruses with wild-type and chimeric env genes
Virusa Virus titerb
Posttransfection
Day 22
Passage 1
Day 12
Passage 2
Day 10
(A) 1.6  107 3.5  106 3.3  106
F(A) 1.9  106 1.6  106 1.4  106
FEXL(A) 1.7 106 1.5  106 1.3  106
FELXL(A) 9.0 105 1.1  106 1.2  106
FEXL3(A) 1.1  106 1.0  106 1.1  106
a See Fig. 1 for explanation of the virus nomenclature and env gene
organization.
b Viral titers were determined by assaying 10-fold serial dilutions of the
infected DF-1 culture supernatants for AP at the times indicated.
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teins specifically bound the anti-FLAG mAb, while only the
viruses with glycoproteins that displayed the EGF ligand
bound an anti-EGF mAb.
To determine if ALV with displayed ligands could spe-
cifically bind a nonviral receptor on the surface of a cell,
CHO cells and CHO cells expressing the human EGF re-
ceptor, CHO-hEGFr, were incubated with ALV containing
different chimeric envelope glycoproteins, F(A) (data not
shown), FEXL(A), FELXL(A), and FEXL3(A), and the
bound ALV virions were detected by FACS (Fig. 3B). Only
ALV displaying EGF mixed with cells expressing the EGF
receptor produced a signal in this assay, indicating specific
binding of the EGF-displaying virions with the EGF recep-
tor on the cell surface. The length and organization of the
amino acid linkers did not appear to affect the interaction of
ALV with the cell since all three viruses with chimeric
glycoproteins that displayed EGF bound to CHO-hEGFr
cells approximately equally. The binding specificity of the
displayed ALV-EGF ligand for the cellular EGF receptor
was demonstrated by the almost complete inhibition of virus
binding in the presence of recombinant EGF competitor, or
after the EGF domains had been cleaved from the virions by
pretreatment with Factor Xa (Fig. 3B).
Nonviral polypeptides displayed on ALV are maintained
for multiple virus passages
One of the advantages of a display technology that uses
a replicating virus lies with the ability to repeatedly amplify
the selected population of display packages. To test whether
the displayed polypeptides on the replication-competent
ALV would be retained upon repeated virus amplifications,
the virus stocks produced from the transfected DF-1 cul-
tures (Fig. 2A; day 22) were used to infect fresh DF-1 cells
and the viruses were allowed to spread through the culture
(Fig. 4A). The sizes of the chimeric envelope glycoproteins
and the presence of the displayed polypeptides were ana-
lyzed by Western immunoblot (Fig. 4B). The virus stocks
Fig. 3. Analysis of the binding specificity of the nonviral ligands displayed on the SU glycoprotein in virions for an appropriate antibody/receptor either
immobilized on a solid support (A) or expressed on the cell surface (B). (A) Plates coated with either a -FLAG mAb or -EGF mAb were incubated with
supernatant from uninfected DF-1 cells (Mock), (A), F(A), FEXL(A), FELXL(A), or FEXL3(A) virus stocks (see Fig. 2A; day 22), washed, and then
incubated with uninfected DF-1 cells. After 2 days, the cells were fixed and assayed for AP activity expressed from the AP gene delivered by the virus (dark
purple precipitate). (B) Parental CHO cells, CHO-Parent, and a CHO cell line that expresses the human EGF receptor, CHO-hEGFr, were incubated with
either (A), FEXL(A), FELXL(A), or FEXL3(A) virus and then washed. The bound ALV virions were detected by FACS using a soluble form of the ALV(A)
receptor that binds to subgroup A SU glycoprotein bound to phycoerythrin. The background level of nonspecific binding is shown with (A) binding (black
histogram). Specific binding of the chimeric viruses is shown with the gray histograms. The viruses were also incubated with cells pretreated with and in
the presence of 2 M recombinant human EGF, CHOhEGFrrEGF. Finally, the viruses were pretreated with Factor Xa protease and then incubated with
cells, CHOhEGFrFxa.
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from this first virus repassage were amplified a second time
(Fig. 4C) and analyzed (Fig. 4D). Viruses with the chimeric
envelope glycoproteins continued to replicate to high titers
in both amplifications, although at a slightly slower rate
(Figs. 4A and C) and to a slightly lower maximum titer
(Table 1) compared to ALV(A) with wild-type glycopro-
teins. All of the chimeric glycoproteins were stably retained
through both virus repassages except FEXL3(A) (Figs. 4B
and D). After repassage 1, the FEXL3(A) chimeric glyco-
proteins migrated over a broader size range compared to the
original FEXL3(A) virus stock (compare Fig. 2C with Fig.
4B), indicating the repassage 1 viral population contained a
detectable level of viruses with the nonviral protein domains
deleted from ALV(A) SU. This population still contained a
high proportion of viruses with intact chimeric glycopro-
teins as shown by the approximately equal levels of the
FLAG and EGF ligands (Fig. 4B). However, after the sec-
ond FEXL3(A) virus repassage, most of the FEXL3(A)
glycoproteins in the viral population now did not contain the
nonviral ligands (Fig. 4D). Why the nonviral polypeptide
and linker organization of the FEXL3(A) env gene and/or
glycoproteins would be selected against by ALV and not the
similar FEXL(A) and FELXL(A) organizations is not
known. FEXL3(A) does contain the longest flexible amino
acid linker (Fig. 1), which may provide a region for efficient
recombination in the genome or possibly cause altered pro-
cessing of the glycoproteins, leading to selection of a more
robust deleted variant.
ALV(A) can also stably display a large cell-binding
polypeptide: a anti-human CEA single-chain antibody
To further explore the size range of polypeptides that can
efficiently and stably be displayed on the ALV(A) SU
glycoprotein, a chimeric env gene was constructed that
encodes a single-chain antibody that recognizes human
CEA (-CEAscFv), FCXL(A) (Fig. 1). A new control
chimeric env was also constructed without the sequences
encoding -CEAscFv, FXL(A). Virus stocks of (A),
FXL(A), and FCXL(A) were produced and repassaged,
and the virus stocks and envelope glycoproteins were ana-
lyzed as above. All three viruses replicated to high titers
during the initial virus production as well as in both virus
repassages (Table 2). No significant differences were ob-
served in the size distributions of the envelope glycopro-
teins or the levels of the FLAG ligand between any of the
virus stocks (Fig. 5A). The larger size of the displayed
nonviral polypeptide did not alter the ability of the virus to
interact with a protein ligand: FCXL(A) virions displaying
the -CEAscFv polypeptide could specifically bind CEA on
the surface of cells as determined by FACS (Fig. 5B).
All of the chimeric ALV(A) tested contained a chimeric
env gene and the 2.0-kb AP reporter gene. The FCXL(A)
virus not only tested the effect of a large nonviral polypro-
tein displayed on SU on virus infection and replication, but
tested the limit of extra sequences that can be stably main-
tained in the viral genome (2.7 kb). The stability of
Fig. 4. Determining the stability of the chimeric envelope glycoproteins upon virus repassage. The virus stocks produced from the transfected DF-1 cultures
(see Fig. 2A; day 22) were repassaged by infecting fresh DF-1 cells at a multiplicity of infection of 0.001 IFU/cell. Viral growth was monitored by ELISA
as before (A) and the integrity of the envelope glycoproteins was assessed by Western immunoblot analysis (B). The SU glycoproteins were analyzed with
a anti-ALV SU mAb [-ALV(A)-SU], and for the presence of the FLAG tag with an anti-FLAG mAb (-FLAG) and the EGF ligand with a anti-EGF mAb
(-EGF). Proteins were also analyzed from uninfected DF-1 cell supernatant (Mock). The antibody bound protein complexes were visualized by
chemiluminescence. A second round of virus repassage was done using virus stocks from day 12 (see A). Viral growth monitoring (C) and SU glycoprotein
analysis (D) were done as described above.
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expression of the FCXL(A) envelope glycoproteins as
well as AP, at least for the three viral passages tested here,
demonstrates the potential versatility of the RCASBP(A)
vectors to not only display complex eukaryotic polypeptides
but also to express a separate nonviral gene. In addition to
the second gene offering the opportunity to include a re-
porter protein to aid in experimental analysis as in this
study, we envisage that this versatility could allow combi-
natorial screening of two different peptide libraries for com-
plex protein interaction phenotypes dependent on two dif-
ferent proteins. The capability of the ALV genome to
maintain large nonviral sequences is another advantage of
ALV over MLV as a display platform: the size range of
insertions into the MLV genome has been shown to be
much more restricted compared to the ALV vectors (Logg
et al., 2001).
The displayed nonviral polypeptides did not alter the
receptor usage of ALV(A)
ALV requires the expression of an appropriate receptor
on the cell surface for efficient infection to occur. The
natural receptor for ALV(A) is Tva, a glycoprotein of un-
known function which is normally expressed only in birds
(Bates et al., 1993; Young et al., 1993). Mammalian cells
are not susceptible to efficient ALV(A) infection unless
engineered to express the Tva receptor. Infection of mam-
malian cells can occur, albeit inefficiently, if ALV(A) has
been pretreated with soluble forms of the Tva receptor
which triggers the envelope glycoproteins to allow nonspe-
cific infection of cells lacking Tva on the cell surface
(Damico and Bates, 2000). We tested whether the fusion of
nonviral domains to the chimeric envelope glycoproteins
had altered the normal receptor usage of the viruses by
infecting a variety of cell types, susceptible (DF-1) and
nonsusceptible (CHO-Parent, CHO-hEGFr) to wild-type
ALV(A) infection, in the presence or absence of soluble
Tva. A representative experiment characterizing the recep-
tor usage of viruses with chimeric glycoproteins compared
to wild-type glycoproteins is shown in Fig. 6. No significant
differences were observed between the abilities of ALV(A)
with wild-type or chimeric envelope glycoproteins to infect
cells directly or in the presence of soluble Tva receptor (Fig.
6A). Viruses with chimeric ALV(A) envelope glycoproteins
still required Tva for efficient entry into cells, a result
consistent with other studies attempting to retarget retroviral
receptor usage (Russell and Cosset, 1999). The presence or
absence of the human EGF receptor (hEGFr) also did not
alter the entry efficiency of ALV with EGF displaying
glycoproteins.
The display of nonviral polypeptides on MLV can have
a profound effect on the ability of the virus to infect cells.
For example, MLV with chimeric envelope glycoproteins
that display the EGF ligand on SU do not efficiently infect
susceptible cells expressing high levels of the EGF receptor,
resulting in a several log decrease in titer on these cells
(Nilson et al., 1996). This block in entry is due to the
displayed EGF ligand on MLV binding the EGF receptor
that sequesters the virus from its normal receptor by inter-
nalizing and degrading the complexes in endosomes. To test
whether a similar block to the entry of ALV(A) displaying
EGF would occur, several DF-1 cell lines that express
different levels of the hEGFr were produced (data not
Table 2
Titers of RCASBP(A)AP viruses with wild-type and chimeric env genes
Virusa Virus titerb
Posttransfection
Day 26
Passage 1
Day 14
Passage 2
Day 14
(A) 3.8  106 3.2  106 2.7  106
FXL(A) 2.0  106 2.2  106 2.4  106
FCXL(A) 1.1 106 1.4  106 1.6  106
a See Fig. 1 for explanation of the virus nomenclature and env gene
organization.
b Viral titers were determined by assaying 10-fold serial dilutions of the
infected DF-1 culture supernatants for AP at the times indicated.
Fig. 5. The display of a single-chain antibody on the ALV SU glycoprotein.
Plasmids encoding molecular clones of either RCASBP(A)AP viruses with
wild-type (A) or chimeric FXL(A) or FCXL(A) env genes were trans-
fected into chicken DF-1 cells and the cultures were propagated (data not
shown). (A) Western immunoblot analysis of viral proteins in virions
collected from day 20 posttransfection supernatants (3 ml). Proteins were
also analyzed from uninfected DF-1 cell supernatant (Mock). The antibody
bound protein complexes were visualized by chemiluminescence. Immu-
noblots were probed with -ALV(A)-SU mAb or -FLAG mAb. The virus
stocks were repassaged two times as described (see Fig. 4). Immunoblots
of the viral proteins were probed as described above. (B) MC-38 cells
(CEA) and a MC-38 cell line that expresses human CEA (CEA) were
incubated with either (A), FXL(A), or FCXL(A) virus and then washed.
The bound ALV virions were detected by FACS using a soluble form of
the ALV(A) receptor that binds to subgroup A SU glycoprotein bound to
phycoerythrin (gray profile). The background level of nonspecific binding
is shown with (A) (black profile).
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shown). In contrast to the MLV case, there was no signif-
icant difference in the infection efficiency of (A), FEXL(A),
FELXL(A), and FEXL3(A) viruses for the parental DF-1
cells and DF-1 cells expressing the EGF receptor. A repre-
sentative experiment characterizing the efficiency of infec-
tion of one DF-1 cell line expressing hEGFr with wild-type
virus and FEXL(A) displaying chimeric glycoproteins with
the EGF domain is shown in Fig. 6B. However, while most
retroviruses enter cells by fusion at the cell surface at
neutral pH, a recent report has proposed another entry path-
way for ALV(A) viruses: a requirement for a low pH envi-
ronment but only after interacting with Tva at the cell
surface (Mothes et al., 2000). Despite this possible ALV
low pH entry requirement, we found no evidence that
ALV(A) displaying EGF could infect cells by interacting
with the EGF receptor even in the presence of soluble Tva
receptor.
Conclusions
We demonstrate that ALV(A) is a versatile viral platform
for the display of polypeptides synthesized in eukaryotic
cells. A wide range of nonviral polypeptide sizes can be
displayed as N-terminal extensions of the ALV(A) SU gly-
coprotein, and the chimeric glycoproteins were efficiently
incorporated into virions. The replication kinetics and the
maximum titers of the ALV(A) with the chimeric glyco-
proteins tested were only slightly lower than virus with
wild-type glycoprotein: titers of the chimeric viruses were
consistently 106 IFU/ml. All combinations of ligands and
amino acid linkers produced virions with the displayed
nonviral ligands accessible to specific binding interactions
with immobilized antibodies against the ligand, and recep-
tors expressed on the surface of cells. The displayed
polypeptides also did not interfere with the normal receptor
usage and entry properties of ALV(A). The ALV(A) ge-
nome stably maintained the chimeric env genes and ex-
pressed the displayed polypeptides fused to the SU glyco-
protein despite their being nonessential for virus replication.
In addition to the extra env sequences coding for the non-
viral polypeptide, the ALV(A) vectors also maintained an
additional sequence in a separate transcription unit, the AP
gene, which significantly increases the versatility of the
display platform.
Materials and methods
Vector construction
The construction of the RCASBP(A)AP retroviral vec-
tor, an ALV-based replication-competent vector with a sub-
group A env gene (A) and the heat stable human placental
alkaline phosphatase gene, has been described (Federspiel
and Hughes, 1997; Fekete and C.L., 1993; Fields-Berry et
al., 1992). Six different recombinant RCASBP(A)AP vi-
ruses were constructed by replacing the wild-type env gene
(A) with chimeric ALV(A) env genes constructed by PCR
encoding envelope glycoproteins with additional epitopes
inserted in-frame at the N-terminus of SU (1) (Fig. 1). All
six recombinant env genes contain an additional 24 nt that
encode the FLAG epitope, DYKDDDDK. The F(A) env
Fig. 6. The efficiency of infecting susceptible and nonsusceptible cells with ALV(A) viruses containing wild-type or chimeric envelope glycoproteins. (A)
The titer of virus stocks containing wild-type (A) or chimeric glycoproteins, FEXL(A), FELXL(A), or FEXL3(A), were determined on DF-1 cells, CHO cells
(CHO-Parent), and CHO cells expressing hEGFr (CHO-hEGFr) directly or after preabsorption with a soluble form of the Tva receptor (sTva) by AP assay.
The * represents a titer of less than 1 IFU/ml, the limit of detection. The data represent the average of two experiments. (B) The titer of virus stocks containing
wild-type (A) or FEXL(A) chimeric glycoproteins were determined on DF-1 cells, and a DF-1 cell line expressing hEGFr (DF1/EGFR-CI.21) directly or after
preabsorption with a soluble form of the Tva receptor (sTva) by AP assay. The data represent the average of two experiments.
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gene only contains the FLAG epitope. Three env genes
contain additional sequences that encode the 51-amino-acid
human epidermal growth factor ligand (Peng et al., 1997),
amino acid linker residues glycine-glycine-glycine-glycine-
serine, and a Factor X protease cleavage site (Fxa), flanked
by SfiI and NotI sites for cloning: FEXL(A), FLAG-SfiI-
EGF-Fxa-G4S-NotI; FELXL(A), FLAG-SfiI-EGF-G4S-Fxa-
G4S-NotI; and FEXL3(A), FLAG-SfiI-EGF-Fxa-G4S-G4S-
G4S-NotI. The FCXL(A) env gene contains sequences that
encode the 244-amino-acid human carcinoembryonic anti-
gen single-chain antibody (-CEAscFv) (Holliger et al.,
1999): FLAG-SfiI--CEAscFv-NotI-Fxa-G4S. The FXL(A)
env gene does not contain the sequences encoding
-CEAscFv: FLAG-SfiI-NotI-Fxa-G4S. The nucleotide se-
quences of all recombinant chimeric env genes were con-
firmed by DNA sequencing.
Cell culture and virus propagation
DF-1 cells, a chicken fibroblast cell line (Himly et al.,
1998; Schaefer-Klein et al., 1998), were grown in Dulbec-
co’s modified Eagle’s medium (GIBCO/BRL) supple-
mented with 10% fetal bovine serum (GIBCO/BRL), 100 U
of penicillin per ml, and 100 g of streptomycin per milli-
liter (Quality Biological, Inc., Gaithersburg, MD) at 39°C
and 5% CO2. Chinese hamster ovary (CHO) cells and
MC-38 cells, a mouse colon adenocarcinoma cell line (Rob-
bins et al., 1991), were grown as above only at 37°C. The
CHO cell line expressing the human EGF-receptor (CHO-
hEGFr) (Schneider et al., 2000) and the MC-38 cell line
expressing human CEA (MC-38-CEA) (Robbins et al.,
1991) were grown in media containing 500 g/ml G418
(GIBCO/BRL). Several DF-1 cell lines expressing human
EGF receptor were generated by transfecting DF-1 cells
with pcDNA3.1()/EGFr (kindly provided by Dr. C. David
James, Mayo Clinic, Rochester, NY), selecting cells with
the expression plasmid with G418 (1 mg/ml), and cloning
individual resistant colonies. The level of hEGFr expressed
by the different cell lines was quantitated by FACS using a
anti-EGFr monoclonal antibody (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA) followed by anti-mouse IgG-PE con-
jugate (Kirkegaard and Perry, Gaithersburg, MD).
Virus propagation was initiated either by transfection of
plasmid DNA that contained the retroviral vector (with
wild-type or chimeric env genes) in proviral form (Feder-
spiel and Hughes, 1997) or by direct infection. In standard
transfections, 10 g of purified plasmid DNA was intro-
duced into DF-1 cells by the calcium phosphate precipita-
tion method (Kingston et al., 1989). Viral spread was mon-
itored by assaying culture supernatants for ALV capsid
protein (CA) by enzyme-linked immunosorbent assay
(ELISA) (Smith et al., 1979). Virus stocks were generated
from cell-culture supernatants. The supernatants were
cleared of cellular debris by centrifugation at 2000 g for 10
min at 4°C and stored in aliquots at 80°C. Virus titers
were determined by mixing 10-fold serial dilutions of the
virus stock with DF-1 cells and assaying for AP activity
48 h later as described previously (Holmen et al., 1999).
Western immunoblots
Virions were collected by ultracentrifugation of viral
supernatants (10 ml) in a SW41 Beckman rotor at 4°C for
1 h at 30,000 rpm. Pellets were resuspended in 100 l of
Spears buffer [1 M Tris pH 7.0, 100 mM dithiothreitol
(DTT), 2% sodium dodecyl sulphate (SDS), 0.1% bromphe-
nol blue, and 10% glycerol] and boiled for 5 min and the
proteins were separated on 12% SDS–acrylamide gels. The
separated proteins were transferred onto nitrocellulose
membranes (Amersham Pharmacia Biotech), blocked with
PBS containing 5% non-fat dry milk and 0.1% Tween 20
(blocking buffer), and incubated for 1 h at 25°C with the
appropriate antisera diluted in blocking buffer: anti-Flag M2
monoclonal antibody (mAb) (Sigma), 1:1500 dilution; anti-
EGF mAb (R&D Systems, Minneapolis, MN), 1:2000 di-
lution: anti-ALV CA sera (Charles River SPAFAS), 1:5000
dilution; and anti-ALV SU(A) mAb, 1:2000 dilution
(Ochsenbauer-Jambor et al., 2002). After extensive washing
with wash buffer (PBS containing 0.1% Tween 20), the
immunoblots were incubated with 50 ng/ml peroxidase-
labeled goat anti-mouse or goat anti-rabbit IgG (HL)
(Kirkegaard and Perry) in blocking buffer for 1 h at 25°C.
After extensive washing, immunodetection of the protein
antibody–peroxidase complex was performed with the
Western blot chemiluminescence reagent (DuPont NEN,
Boston, MA) and exposed to Kodak X-OMAT film. For
Factor Xa cleavage, the pelleted virus particles were first
resuspend in 100 l OptiMem media (Gibco/BRL) and then
incubated with 4 g/mL of Factor Xa protease (New En-
gland Biolabs, Beverly, MA) in the presence of 2.5 mM
CaCl2 for 90 min at 37°C. The protease digestions were
separated and immunoblotted as described above.
Infectious retrovirus immunosorbent assay (IRISA)
The IRISA assay was a modification of the procedure
published previously (Russell et al., 1993). In short, plates
were coated with either anti-Flag mAb or anti-EGF mAb (5
g/ml) in PBS containing 2% fetal calf serum overnight at
4°C. The next day, the plates were washed three times with
PBS and nonspecific protein binding blocked with PBS
containing 5% bovine serum albumin for 2 h at 37°C. Plates
were washed three times with PBS and incubated with
RCASBP(A)AP virus stocks containing wild-type or chi-
meric env genes for 2 h at 4°C. The plates were washed
extensively with PBS to remove unbound virus and then
fresh DF-1 cells were added and the cultures were incubated
for 2 days. Infected cells were assayed for AP activity as
described previously (Holmen et al., 1999).
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Virus binding assays
Target cells were washed in PBS and detached from the
plate with versene (Gibco/BRL) for 5-min at 37°C, and the
cell suspension was washed with PBS containing 2% fetal
calf serum (PBS-CS). Supernatants with viruses with wild-
type or chimeric env genes were incubated with 1  106
washed cells for 1 h at 4°C, and the cell/virus mixture was
washed three times with PBS-CS to remove unbound virus.
The washed cell/virus mixture was then incubated with a
soluble form of the quail ALV(A) receptor Tva fused to a
mouse IgG tag (sTva-mIgG) Holmen et al., 1999, 2001 for
1 h at 4°C. The sTva-mIgG will efficiently bind to the SU
of the ALV(A)/cell complexes. The mixture was washed
extensively with PBS-CS and then incubated with 5 g/ml
of phycoerythrin-labeled goat anti-mouse IgG (HL)
(Kirkegaard & Perry Laboratories) in PBS-CS for 30 min on
ice. After washing with PBS-CS, the mixture was resus-
pended in 0.5 ml of PBS-CS and the fluorescence (excita-
tion 488 nm, emission 585  21 nm) was analyzed with a
Becton–Dickinson FACSCalibur using CELLQuest 3.1
software. For a competitive binding assay, the CHO-hEGFr
cells were preincubated with 2 M recombinant human
EGF (R&D Systems) in PBS-CS at 4°C for 1 h, followed by
the virus binding assay as described above.
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